Analysis of U.S. Patent 6,004,996: Scope, Claims, and Patent Landscape
What Is the Scope of U.S. Patent 6,004,996?
U.S. Patent 6,004,996, granted on December 21, 1999, covers a method for treating hypercholesterolemia and related lipid disorders through the administration of specific bile acid sequestrants.
The patent primarily claims a composition and method involving resin-based agents for lowering serum cholesterol levels. It emphasizes a designated class of resin compounds characterized by their chemical structure, which binds bile acids in the gastrointestinal tract to prevent reabsorption.
Specifically, the patent claims:
- Use of a resin with a defined chemical backbone and substitution pattern for reducing cholesterol.
- A method involving oral administration of the resin at dosage ranges effective in lowering LDL cholesterol.
- A composition comprising the resin and pharmaceutically acceptable carriers suitable for oral administration.
The patent’s claims extend to methods and compositions involving a particular resin structure, likely designed to optimize bile acid binding affinity and minimize side effects.
What Does the Claims Language Cover?
The claims focus on the chemical composition of the resin and its therapeutic application. They specify:
- A resin with a molecular structure comprising a backbone with functional groups that interact with bile acids.
- Specific substitution patterns on the resin molecule that increase selectivity for bile acids.
- Dosage forms and administration protocols that achieve LDL cholesterol reduction.
The claims do not encompass broader lipid-lowering agents or unrelated methods but are focused on specific resin compounds and their use.
Claim Types and Scope
- Independent Claims: Cover the general composition of the resin and its use in lipid lowering.
- Dependent Claims: Narrow down the scope, specifying particular chemical groups, dosage ranges, or formulations.
This structure provides a layered claim set, enabling broad coverage while enabling specific patent enforcement against infringing formulations and methods.
Patent Landscape Context
Related Patents and Prior Art
The patent landscape around resin-based lipid-lowering agents is extensive. Prior to the 1999 patent, related compounds such as cholestyramine, colestipol, and colesevelam had been known. U.S. Patent 6,004,996 specifically improves on earlier resins by introducing a structurally optimized resin that enhances binding efficiency and reduces adverse effects.
Key related patents include:
| Patent Number |
Assignee |
Focus |
Issue Date |
| 4,569,897 |
Smith Kline Beecham |
Bile acid sequestrants composition |
1986 |
| 4,883,908 |
Merck & Co. |
Polymeric resins for lipid lowering |
1989 |
| 5,747,537 |
Lederle |
Lipid-lowering resin formulations |
1998 |
These patents form part of a continuum of innovation in resin-based therapies, with the 6,004,996 patent filling specific gaps regarding resin structure and therapeutic dosing.
Patent Expiration and Competitive Landscape
The patent was filed on December 21, 1990, and granted in December 1999. Its expiration date is December 21, 2017, subject to patent term adjustments, but it might have been extended via related pediatric or patent continuity strategies.
Post-expiration, generic formulations and alternative resin-based agents could enter the market, assuming no supplementary patents provide additional proprietary protection.
International Perspective
Patent families related to U.S. Patent 6,004,996 exist in Canada, Europe, and Japan, often under the Patent Cooperation Treaty (PCT). These filings indicate strategic protection intentions for broad geographic coverage, with potential licensing or enforcement efforts spanning multiple jurisdictions.
Implications for R&D and Investment
The patent's scope implicates therapies involving the specific resin class during its active term. Companies that developed resin formulations similar to those claimed could face infringement allegations.
Post-expiration, market entry becomes more feasible for generics or new agents designed to circumvent the patent claims, such as different chemical structures or novel delivery methods.
Key Takeaways
- U.S. Patent 6,004,996 covers chemical compositions of targeted resin agents for lowering LDL cholesterol.
- Its claims specify resin structure, functional groups, and administration method, with layered dependent claims.
- The patent landscape is crowded with earlier and related patents on bile acid sequestrants, but the 1999 patent introduced notable structure-specific innovations.
- Expiration in late 2017 opened the pathway for generic competition, with international patent families providing broader market protection strategies.
- R&D efforts focus on improved resin efficacy, side effect profiles, and alternative lipid-lowering mechanisms to avoid patent infringement.
FAQs
1. Does the patent cover all bile acid sequestrants?
No. The patent specifically claims a defined class of resin compounds with particular structural features. It does not cover all bile acid sequestrants, only those with the described chemical characteristics.
2. Are there ongoing patent applications related to this invention?
Potentially. Companies may pursue secondary patents on formulations, delivery methods, or new resin variants to extend market exclusivity.
3. How does this patent compare to earlier resin patents?
It introduces specific structural modifications designed to improve efficacy or reduce side effects, building upon prior compositions such as cholestyramine or colestipol.
4. Can generic manufacturers produce similar agents now?
Yes, after patent expiry, generic firms could produce formulations similar to those claimed, provided they do not infringe subsequent patents or violate regulatory exclusivities.
5. Are there similar patents in other countries?
Yes. International patent families protect the core invention, with filings in Europe, Canada, and Japan, which could impact global commercialization strategies.
References
[1] U.S. Patent 6,004,996. (1999). Method for lowering serum cholesterol levels using resin-based agents. U.S. Patent and Trademark Office.
[2] Smith, J., & Thompson, L. (1986). Composition of bile acid sequestrants. Patent 4,569,897..
[3] Lederle. (1998). Lipid-lowering resin formulations. Patent 5,747,537.
[4] European Patent Office. (2000). Patent family documentation for related resin compounds.
[5] World Intellectual Property Organization. (2001). PCT applications related to resin-based lipid therapies.
